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Key Points




Bendamustine with
rituximab is a highly
effective frontline
therapy in extranodal
marginal zone
lymphoma across all
extranodal sites.
Bendamustine with
rituximab overcomes
known poor prognosis
features in extranodal
marginal zone
lymphoma.

Extranodal marginal zone lymphoma (EMZL) is a heterogeneous non-Hodgkin
lymphoma. No consensus exists regarding the standard-of-care in patients with
advanced-stage disease. Current recommendations are largely adapted from follicular
lymphoma, for which bendamustine with rituximab (BR) is an established approach. We
analyzed the safety and efﬁcacy of frontline BR in EMZL using a large international
consortium. We included 237 patients with a median age of 63 years (range, 21-85). Most
patients presented with Eastern Cooperative Oncology Group (ECOG) performance status
0 to 1 (n 5 228; 96.2%), stage III/IV (n 5 179; 75.5%), and intermediate (49.8%) or high
(33.3%) Mucosa Associated Lymphoid Tissue International Prognosis Index (MALT-IPI).
Patients received a median of 6 (range, 1-8) cycles of BR, and 20.3% (n 5 48) received
rituximab maintenance. Thirteen percent experienced infectious complications during
BR therapy; herpes zoster (4%) was the most common. Overall response rate was 93.2%
with 81% complete responses. Estimated 5-year progression-free survival (PFS) and
overall survival (OS) were 80.5% (95% CI, 73.1% to 86%) and 89.6% (95% CI, 83.1% to
93.6%), respectively. MALT-IPI failed to predict outcomes. In the multivariable model, the
presence of B symptoms was associated with shorter PFS. Rituximab maintenance was
associated with longer PFS (hazard ratio 5 0.16; 95% CI, 0.04-0.71; P 5 .016) but did not
impact OS. BR is a highly effective upfront regimen in EMZL, providing durable
remissions and overcoming known adverse prognosis factors. This regimen is associated
with occurrence of herpes zoster; thus, prophylactic treatment may be considered.

Submitted 16 December 2021; accepted 13 February 2022; prepublished online on
Blood Advances First Edition 23 February 2022; ﬁnal version published online 29 March
2022. DOI 10.1182/bloodadvances.2021006844.
Qualiﬁed researchers may request nonconﬁdential data from the corresponding
author at ilossos@med.miami.edu.
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Introduction

Several agents have been tested in patients with untreated EMZL,
including single-agent rituximab,13,14 lenalidomide with rituximab,15,16 R-CVP (rituximab, cyclophosphamide, vincristine, and
prednisolone),17,18 R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone),19,20 and others. The International
Extranodal Lymphoma Study Group (IELSG) 19 remains the only
phase 3 study focusing on the frontline treatment of EMZL. This
study randomized 454 patients to the combination of rituximab with
chlorambucil, single-agent chlorambucil, or single-agent rituximab.
The combination arm led to signiﬁcantly longer 5-year event-free survival (EFS) (68%) compared with single-agent chlorambucil (51%)
or rituximab (50%; P 5 .0009), without signiﬁcant toxicity noted in
any treatment arm.21 Although chlorambucil with rituximab had
shown superior efﬁcacy in a randomized study, this regimen has not
gained wide acceptance in the United States, and novel therapies
were subsequently developed.22
The National Comprehensive Cancer Network guidelines list bendamustine combined with rituximab (BR) as 1 of 3 preferred regimens
in EMZL.22 However, data supporting this regimen in EMZL are limited. Two randomized clinical trials tested BR vs R-CHOP and/or
R-CVP but largely included patients with follicular lymphoma.18,23 A
relatively small number of patients with MZL was enrolled in these
studies, and both clinical trials analyzed all MZL subtypes as a single entity. The MALT2008-01 is the largest study testing BR in
patients with untreated EMZL. Following a response-adapted
approach, 57 evaluable patients received BR with a complete
response (CR) and unconﬁrmed CR (CRu) rate of 98%, associated
with a 7-year EFS rate of 88%. No differences in response rate or
survival by disease location or presence of t(11;18) were
observed.24,25

Expert pathology review was performed at each participating institution using the World Health Organization classiﬁcation without central pathology review.1 Staging evaluation and therapy for patients
were completed at the discretion of treating physicians and following local institutional standards. Opportunistic infection prophylaxis
was given according to institutional guidelines.
Investigators collected detailed demographic, clinicopathologic, laboratory, treatment, and outcome data using a standardized protocol.
Demographic and clinical characteristics were summarized using
descriptive statistics. Performance status (PS) was assigned
according to the Eastern Cooperative Oncology Group (ECOG)
scale. Serum lactate dehydrogenase (LDH) was considered elevated based on the institutional upper limit of normal. The mucosaassociated lymphoid tissue International Prognosis Index (MALT-IPI)
was calculated as previously described.27 Patients with EMZL
located in the skin, adipose tissue, fascia, and skeletal muscle were
included in soft tissue extranodal site. Progression-free survival
(PFS) was deﬁned as the time from diagnosis to progression,
relapse, death, or last follow-up, whichever occurred ﬁrst. Overall
survival (OS) was deﬁned as the time from diagnosis to death or
last follow-up. Event-free patients were censored at the date of last
follow-up. PFS and OS were estimated by Kaplan-Meier method
and associations with prognostic factors assessed by log-rank test,
univariable and multivariable Cox proportional-hazard regression
models. Multivariable Cox model was constructed by selecting

274 patients with EMZL
(January 2008 to
September 2020)

Not eligible
• EMZL located only in bone
marrow (n 26)
• Unknown EMZL location (n 8)
• No data on BR initiation dates
(n 3)

Considering the small number of patients with MZL enrolled in clinical trials, larger observational studies are needed to provide more
accurate data on safety and efﬁcacy of BR in untreated EMZL.
Therefore, we explored BR activity in EMZL as part of an international consortium created to address this question.
237 patients

Methods
The consortium, comprised of 20 institutions from Italy and the
United States, identiﬁed 274 adult patients with EMZL treated with
2036
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Figure 1. CONSORT diagram.
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Extranodal marginal zone lymphoma (EMZL) of mucosa-associated
lymphoid tissue is a rare disease representing 5% to 8% of all
B-cell lymphomas.1,2 EMZL may arise at any mucosal site but most
commonly involves the stomach (30%), followed by ocular adnexa
(12%), skin (10%), lung (9%), and salivary gland (7%).3 EMZL is
generally diagnosed at an early stage, remaining conﬁned to the site
of origin for a prolonged time.4,5 In patients with stage I EMZL of
any location, including those with gastric involvement after failure of
Helicobacter pylori eradication therapy, the preferred approach is
radiation therapy.6-11 However, 20% to 40% of patients with EMZL
present with advanced-stage disease that is associated with inferior
outcomes.5,12 The treatment approach in patients with advancedstage disease remains controversial, and there is lack of consensus
for the choice of ﬁrst-line therapy and number of treatment cycles in
the absence of randomized clinical trial data.

frontline BR from January 2008 to September 2020. Patients with
prior radiation therapy, surgery, or H. pylori eradication therapy were
allowed. Prior rituximab or other systemic therapies were excluded.
Patients with the following factors were excluded from the study:
EMZL located only in bone marrow to avoid potential inclusion of
cases with lymphoplasmacytic lymphoma, unknown EMZL location,
and absence of data on BR initiation dates (Figure 1). A total of
237 patients were included in this analysis, including 182 patients
with EMZL in whom pertinent data were collected retrospectively
and 55 patients prospectively enrolled in the NF10 project from the
Fondazione Italiana Linfomi treated with frontline BR from January
2008 to December 2019.26 The study was approved by the institutional review boards of all participating institutions and performed in
accordance with the Declaration of Helsinki.

variables signiﬁcant in the univariable analysis with a P value of
,.05. Statistical analyses were performed using SAS version 9.4
(SAS Institute Inc., Cary, NC).

Table 1. Baseline patient’s characteristics
Variable

N

%

Age

Results

,70 y

176

74.3

Baseline characteristics

$70 y

61

25.7

Female

128

54.0

Male

109

46.0

192

81.0

14

5.9

Treatment characteristics
The median time from diagnosis to BR therapy was 56 (interquartile
range 31-98) (95% CI, 49-64) days with a median of 6 cycles
(range, 1-8) in persons with available data (n 5 181). Rituximab
maintenance was administered in 48 patients (20.3%) with a
median duration of 16 months. Nine (3.8%) patients received consolidation with involved site radiation therapy. Treatment response
was evaluated with PET/CT in 140 patients (59%) and with CT
scans in the rest. The overall response rate (ORR) to frontline BR
was 93.2% with a CR rate of 81% and partial response (PR) rate
of 12.2%. In patients assessed for response by PET/CT, the ORR
was 96.5% with CR of 82.9%. In patients assessed for response
by CT, the ORR was 92.5% with CR of 81.7%. Patients with localized disease (stage I-II) experienced higher rates of CR compared
with those with advanced stage (III-IV) (93% vs 79%; P 5 .016,
respectively).
The incidence of infectious complications during BR therapy was
13% among 180 patients with data. Among those patients, we
observed 7 cases of herpes zoster reactivation (4%), 5 cases of
pneumonia (3%), and inﬂuenza (3%). In patients treated with rituximab maintenance, 3 patients experienced neutropenia (6.2%) and
we observed 1 case of herpes zoster reactivation (2%) and facial
cellulitis (2%). Eight patients (3.4%) developed secondary malignancies after BR treatment, including one case each of acute myeloid
leukemia and squamous cell carcinoma of the skin.
12 APRIL 2022 • VOLUME 6, NUMBER 7

Race/ethnicity
Non-Hispanic white
Hispanic white
African American

18

7.6

Other

13

5.5

58

24.5

179

75.5

0

154

65.0

1

74

31.2

2

9

3.8

Tumor stage
Stage I-II (early stage)
Stage III-IV (advanced stage)
ECOG performance status*

B symptoms*
Non-B symptoms

195

82.3

42

17.7

192

81.0

45

19.0

1

130

54.9

$2

107

45.1

1

0.4

B symptoms
LDH*
Normal LDH
Elevated LDH
Number of extranodal site

Unknown
Bone marrow involvement
Negative

144

60.8

Positive

64

27.0

Unknown

29

12.2

0

40

16.9

1

118

49.8

79

33.3

MALT-IPI score

2-3

Adjust study site as random effect. NE, not estimable.
ECOG PS, Eastern Cooperative Oncology Group performance status; LDH, lactate
dehydrogenase; MALT-IPI, Mucosa associated lymphoid tissue International Prognostic Index.
*Missing values included in normal/no symptoms categories.

Survival analysis
Thirty-six patients had progression of disease and 18 died. With a
median follow-up of 3.21 years (range, 0-10.75), the estimated
5-year PFS and OS were 80.5% (95% CI, 73.1% to 86.0%) and
89.6% (95% CI, 83.1% to 93.6%), respectively (Figure 2A-B). The
5-year cumulative incidence of lymphoma-speciﬁc death was 3.8%
(95% CI, 1.6% to 7.7%) with only 8 deaths attributable to lymphoma. The causes of death in the other 10 patients were head
BENDAMUSTINE AND RITUXIMAB IN UNTREATED EMZL
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In total, 237 patients with EMZL treated with frontline BR were identiﬁed. Median age at diagnosis was 63 years (range, 21-85) with a
female to male ratio of 1.2:1. Prior history of autoimmune disease
was present in 29 patients (12%), with Hashimoto’s thyroiditis and
rheumatoid arthritis (each in 4 patients) constituting the most common diseases. Most patients had ECOG PS 0-1 (65% PS 0,
31.2% PS 1). Staging studies at baseline included computed
tomography (CT) scan in 68 (28.7%) and positron emission tomography (PET)/CT in 169 patients (71.3%). One hundred seventy-nine
(75.5%) patients had advanced-stage (III-IV) disease; however, elevated LDH (19%; n 5 45) and B symptoms (17.7%; n 5 42) were
uncommon. Most patients had no bone marrow involvement (60.8%;
n 5 144) and had fewer than 4 nodal sites (79.7%; n 5 189). Most
patients had 1 extranodal site of disease (54.9%; n 5 130), followed
by 2 sites in 27.4% (n 5 65) and 3 in 12.7% (n 5 30). Common
extranodal sites included lung (25.3%; n 5 60) followed by stomach
(17.3%; n 5 41) and soft tissue (10.1%; n 5 24). Only 2 patients
had H. pylori-associated gastric EMZL (4.4%), and both had experienced failure of antibiotic therapy before receiving BR. The MALT-IPI
risk was intermediate (1 risk factor) in 49.8% and high ($2 risk factors) in 33.3% of patients (Table 1). Presence of paraprotein was
examined in 160 (67.5%) patients and was present in 63 (39.4%).
IgM was the most common paraprotein (40 patients: IgM k: 24,
IgM l: 8, and unspeciﬁed: 8), followed by IgG (IgG l and k 5
cases each), free light chain (4 cases), 2 paraproteins (2 patients),
and unknown (7 patients).

Sex

B

100
75
50

75

50

25

2

0

4

6

8

25
Events/N Yrs
% (95% Cl)
18/237
2 95.3 (91.4–97.4%)
5 89.6 (83.1–93.6%)

0
10

0

2

4

0
10

77

27

11

1

237

E

100

172

28

12

1

Yes 48
No 173

F

0

2

4

8

6

OS (%)

PFS (%)

0

25

Extranodal site
Non-gastric
Gastric
p 0.8853

0

10

0

2

Years
No. at risk
25

15

6

1

No 173

125

60

13

6

0

15
12

6
5

1
0

Extranodal site
Non-gastric
Gastric
p 0.4866

25

HR (95% Cl)
Reference
1.07 (0.44–2.57)

0

4

8

6

10

0

2

Non-gastric 196
Gastric 41

4

6

8

10

No. at risk

135

67

24

10

1

28

10

3

1

0

H

100

HR (95% Cl)
Reference
1.48 (0.49–4.51)

Years
Non-gastric 196
Gastric 41

144

76

25

11

1

28

10

3

1

0

100
75

OS (%)

75

PFS (%)

23
54

50

No. at risk

42

G

42
118

Years

Yes 48

10

75

50

Rituximab maintenance HR (95% Cl)
Yes
0.26 (0.03–2.05)
No
Reference
p 0.1688

8

100

75

50

6

No. at risk
86

100

75

25

4

Years

No. at risk

163

2

0

Years

No. at risk
237

8

6

Rituximab maintenance HR (95% Cl)
Yes
0.18 (0.04–0.80)
No
Reference
p 0.0121

50
MALT-IPI scores
MALT-IPI 0
MALT-IPI 1
MALT-IPI 2–3

25

HR (95% Cl)
Reference
1.83 (0.62–5.41)
2.36 (0.77–7.20)

0

2

MALT-IPI scores
MALT-IPI 0
MALT-IPI 1
MALT-IPI 2–3

25

p 0.3003

0

50

p 0.2114

0
4

6

8

10

HR (95% Cl)
Reference
4.99 (0.65–38.39)
3.37 (0.39–28.97)

0

2

Years

4

6

8

10

Years

No. at risk

No. at risk

MALT-IPI 0 40

31

19

6

3

0

MALT-IPI 0 40

33

21

6

3

0

MALT-IPI 1 118

77

41

17

6

1

MALT-IPI 1 118

82

45

18

7

1

55

17

4

2

0

57

20

4

2

0

MALT-IPI 2–3 79

MALT-IPI 2–3 79

Figure 2. Survival of EMZL patient treated with BR. PFS (A) and OS (B) in patients with extranodal marginal zone lymphoma treated with bendamustine and rituximab;
by rituximab maintenance (C-D); by disease location (E-F); and by MALT-IPI risk group (G-H).

trauma, lung cancer, liver cirrhosis/hepatocellular carcinoma, respiratory failure, bladder cancer, acute myeloid leukemia, heart arrhythmia, and amyotrophic lateral sclerosis, each in 1 patient and
unknown in 2. No difference in PFS was observed among patients
achieving CR or PR after BR (hazard ration [HR]: 0.47; 95% CI,
2038
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0.18-1.27; P 5 .12). We did not observe better PFS by number of
BR cycles (P 5 .222). However, we observed shorter OS in
patients treated with 1 to 3 cycles (P 5 .009; data not shown).
Patients treated with rituximab maintenance after achieving CR or
PR following BR treatment exhibited longer PFS (5-year rate
12 APRIL 2022 • VOLUME 6, NUMBER 7
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Years

OS (%)

50

25
Events/N Yrs
% (95% Cl)
36/237
2 90.1 (85.2–93.5%)
5 80.5 (73.1–86.0%)

0

D

100

75

OS (%)

PFS (%)

C

100

PFS (%)

A

Table 2. UVA Cox models for PFS and OS
PFS
Variable

Category
,70 y

Age

$70 y
Female

Sex

Male
Non-Hispanic white

Race/ethnicity

.040

1.74 (0.64, 4.71)

.258

0.83 (0.32, 2.18)

Reference

Reference

Other

1.19 (0.28, 5.01)

.814

B symptoms

Elevated LDH
,4

Number of nodal sites

$4
Negative
Positive
0

MALT-IPI

1.46 (0.29, 7.49)

.648

NE
1.15 (0.15, 8.91)

.893

Reference

1.31 (0.59, 2.88)

.503

Reference

0.98 (0.35, 2.78)

.970

Reference

2.56 (1.25, 5.24)

.010

Reference

2.35 (0.82, 6.78)

.113

Reference

1.10 (0.48, 2.52)

.821

Reference

1.28 (0.41, 3.98)

.665

Reference

1.03 (0.44, 2.38)

.948

2.05 (0.69, 6.10)

.227

0.40 (0.09, 1.80)

Reference

.197

Reference

0.57 (0.23, 1.41)

.232

Reference

1

1.83 (0.62, 5.43)

.274

5.01 (0.65, 38.81)

.123

2-3

2.36 (0.77, 7.21)

.132

3.28 (0.38, 28.34)

.281

Yes
Complete response
Noncomplete response
$6

Cycles of bendamustine and rituximab

Reference

Reference

No

Rituximab maintenance

.712

Reference

Reference

0.18 (0.04, 0.79)

.023

Reference

0.24 (0.03, 1.95)

.184

Reference

5.31 (2.63, 10.73)

,.001

Reference

4.67 (1.71, 12.79)

.003

Reference

4-5

1.63 (0.69, 3.84)

.268

2.24 (0.69, 7.29)

.180

1-3

2.25 (0.77, 6.56)

.139

5.19 (1.60, 16.90)

.006

Table 3. Multivariable Cox models for PFS and OS
PFS (36 events)
Variable

Category
No B symptoms

B symptoms

B symptoms
0

MALT-IPI scores

P

Reference

2.56 (1.18, 5.52)

.017

Reference

2.15 (0.69, 6.67)

.184

Reference

1.68 (0.54, 5.20)

.371

3.91 (0.48, 31.99)

.203

1.79 (0.55, 5.81)

.333

1.80 (0.19, 16.76)

.607

Yes

Noncomplete response
Cycles of bendamustine and rituximab

HR (95% CI)

1

Complete response

Clinical response

P

Reference

2-3
No

Rituximab maintenance

HR (95% CI)

OS (18 events)

$6

Reference

Reference

0.15 (0.03, 0.65)

.012

Reference

0.17 (0.02, 1.33)

.091

Reference

2.00 (0.73, 5.52)
Not included

.180

0.52 (0.05, 5.01)

.569

Reference

4-5

2.56 (0.75, 8.79)

.134

1-3

2.84 (0.60, 13.39)

.186
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.261

Normal LDH

.279

Reference
.746

III-IV

P

Reference

0.67 (0.34, 1.33)

0.32 (0.04, 2.35)

No B symptoms

Clinical response

2.07 (1.03, 4.14)

1.22 (0.36, 4.13)

B symptoms

HR (95% CI)
Reference

Hispanic white

I-II

Bone marrow involvement

P

Reference

African American

Tumor stage

LDH

HR (95% CI)

OS

included an anthracycline-based regimen with R-CHOP in 7 patients
and dose-adjusted infusional etoposide, doxorubicin, vincristine,
prednisone, cyclophosphamide, and rituximab (DA-EPOCH-R) regimen in 3 patients; 1 patient opted for hospice. Three patients underwent consolidation with autologous stem cell transplant, with 2
patients (66.7%) alive at last follow-up. In 7 patients not treated with
autologous stem cell transplant, 4 (57%) remain alive with a median
follow-up of 2.76 years (95% CI, 0.91-5.95) by reverse KaplanMeier method.

10

HGT cumulative incidence (%)

8

6

4

Discussion
Events/N
11/237

Yrs
5
10

% (95% Cl)
6.0 (2.9–10.8%)
9.1 (3.6–17.8%)

0
0

2

4

6

8

10

27

11

1

Years
No. at risk
237

169

84

Figure 3. Kaplan-Meier curve for cumulative incidence of HGT with dead
as competing risk.

94.4% vs 81.1%; P 5 .0121) with no difference in OS (P 5 .168)
(Figure 2C-D). We did not observe differences in PFS or OS
comparing gastric vs other EMZL locations (PFS P 5 .885 and OS
P 5 .486) (Figure 2E-F). Interestingly, MALT-IPI score did not predict PFS and OS (Figure 2G-H). We were not able to estimate the
effect of progression of disease within 24 months (POD24) on
outcomes in this cohort due to few early events (n 5 21).
Variables associated with shorter PFS in univariable Cox regression
analysis were age $70 years (HR 5 2.07; 95% CI, 1.03-4.14; P 5
.040), B symptoms (HR 5 2.56; 95% CI, 1.25-5.24; P 5 .01), and
not attaining a CR (HR 5 5.31; 95% CI, 2.63-10.73; P , .001),
while rituximab maintenance (HR 5 0.18; 95% CI, 0.04-0.79;
P 5 .023) was associated with longer PFS. The variables associated with shorter OS were not attaining CR (HR 5 4.67; 95% CI,
1.71-12.79; P 5 .003) and treatment with 1 to 3 cycles of BR
(HR 5 5.19; 95% CI, 1.60-16.90; P 5 .006) (Table 2). In a multivariable Cox model, presence of B symptoms and absence of rituximab maintenance were signiﬁcantly associated with shorter PFS;
no variables were associated with OS, likely due to a small number
of events (Table 3).
Higher grade transformation. During the follow-up period,
11 patients (4.6%) developed biopsy-conﬁrmed higher-grade transformation (HGT) to diffuse large B-cell lymphoma, with most demonstrating a nongerminal center phenotype (55.6%). The cumulative
incidence of HGT at 5 and 10 years with death as competing risk
was 6% (95% CI, 2.9% to 10.8%) and 9.1% (95% CI, 3.6% to
17.8%), respectively (Figure 3). The median time to HGT was 0.74
(range, 0.37-5.79) years. Patients experiencing HGT had higher
median standardized uptake values on diagnostic PET/CT than
patients who did not experience transformation (18 vs 6.7; P 5 .016,
respectively). The median number of BR cycles in those patients with
subsequent HGT was 6 (range, 3-6). Only 1 (9%) patient treated
with rituximab maintenance experienced HGT. Treatments for HGT
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To our knowledge, this study represents the largest efﬁcacy analysis
of BR in untreated EMZL. The main ﬁndings of our study are as follows: (1) BR is a highly effective frontline therapy in EMZL, with an
ORR of 93.2% and CR rate of 81%, taking into account disease
across all extranodal sites; (2) rituximab maintenance was associated with longer PFS without affecting OS; (3) frequent infectious
complications, including herpes zoster reactivation, pneumonia, and
inﬂuenza, were noted with BR, which have not previously been
reported in MZL clinical trials; (4) MALT-IPI lacked predictive value;
and (5) few progression and death events occurred within the ﬁrst
24 months after BR treatment.
Two randomized clinical trials have previously tested BR in MZL.
The Study Group for Indolent Lymphomas (StiL) demonstrated signiﬁcantly longer PFS in a phase 3 noninferiority study in which BR
was compared with R-CHOP in indolent and mantle cell lymphomas. However, median PFS was not signiﬁcantly different among
37 patients with MZL treated with BR compared with 30 patients
treated with R-CHOP (57.2 vs 47.2 months; P 5 .32, respectively).23 The BRIGHT study randomized patients to BR vs R-CHOP
or R-CVP. In this study, 46 patients with MZL (BR arm: 28 and RCHOP/R-CVP arm: 18) were included, achieving an ORR of 92%
with a CR rate of 20%; however, the CR rate ratio in indolent
non-Hodgkin lymphoma group was not signiﬁcantly better for BR
compared with R-CHOP/R-CVP (rate ratio 5 1.16; P 5 .129).18
Our results are consistent with the excellent responses observed by
Salar et al in the MALT2008-01 trial, although we observed lower
CR rates (81% compared with 98%).24 Contrary to our study, the
MALT2008-01 cohort included 66% of treated patients with
limited-stage disease while 75.5% of our patients had advancedstage disease. In MALT2008-01, patients received BR in a
response-adapted approach for which response was evaluated after
3 cycles and those achieving CR received a total of 4 cycles,
whereas patients achieving PR received a total of 6 cycles. After 3
cycles, 75% (n 5 43) of the patients achieved CR/CRu, with only
14 patients requiring completion of 6 cycles. Overall, the CR/CRu
rate was 98%, with median duration of response not reached.24
Whether this approach can be applied with similar efﬁcacy to
patients with advanced-stage disease needs further evaluation,
because in our retrospective analysis, CR rate was lower and most
patients received 6 cycles of BR. In MALT2008-01,24 patients
achieving CR after the initial 3 cycles were mainly those with gastric
and multifocal site involvement compared with those with nongastric
locations (P 5 .0226). In contrast, we observed similar responses
and survival in patients with gastric and nongastric EMZL. However,
in the IELSG-19 study, patients with gastric EMZL demonstrated
better 5-year EFS (62% vs 53%; P 5 .024), 5-year PFS (71% vs
57%; P 5 .001) and CR rates (72% vs 61%; P 5 .015) compared
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with nongastric locations.21 Therefore, it is possible that BR may
overcome poorer results obtained in patients with nongastric EMZL.

Evidence supporting rituximab maintenance in EMZL is limited without prior data after frontline BR. The ECOG E4402 study tested
maintenance rituximab vs retreatment in asymptomatic and low
tumor burden patients with indolent lymphoma who had responded
to rituximab.30 This study included 71 patients with MZL (29 with
EMZL), most of whom achieved stable disease after rituximab induction (ORR: 39.5% and CR rate: 15.8%). The maintenance arm
achieved longer time to rituximab failure compared with retreatment
arm (5-year treatment failure-free 45% vs 20%; P 5 .012) in
patients with small lymphocytic lymphoma and MZL without speciﬁc
data on EMZL. The only study testing rituximab maintenance after
BR induction is the StiL NHL7-2008 MAINTAIN trial presented so
far in an abstract form.31 In this study, 119 patients with nodal and
splenic MZL were randomized to rituximab maintenance vs observation after response to BR with a signiﬁcant PFS beneﬁt in the maintenance arm (median PFS not reached vs 92.2 months, HR 5
0.35; 95% CI, 0.17-0.76; P 5 .008) although patients with EMZL
were excluded from this study.31 Similarly, a preliminary report from
the IELSG group examined the role of subcutaneous rituximab maintenance following frontline therapy with rituximab and chlorambucil
in patients with EMZL achieving CR, PR, or stable disease.32 The
CR rate at the end of induction in the intent-to-treat population (n 5
112) was 53% (gastric 69% and nongastric 45%). After 1 year of
maintenance, 70 evaluable patients demonstrated a CR rate of
69%, PR: 26%, stable disease 2.5%, and progressive disease
2.5%. Interestingly, among the 30 patients who achieved PR at the
end of induction, 30% (n 5 9) had an improved response of CR
after 1 year of maintenance rituximab. As with follicular lymphoma,33,34 our data demonstrated longer PFS in EMZL with the
use of rituximab after frontline BR without impacting the OS. However, several caveats need to be considered when interpreting these
data: a short median follow-up (3 years) mainly censoring early
events, underscoring the need for longer follow-up to capture late
events; small number of patients (n 5 48) selected for rituximab
maintenance; and, more importantly, the absence of randomization
regarding which patients received rituximab maintenance. Furthermore, the concerning number of fatal events observed in the GALLIUM study with anti-CD20 maintenance after a bendamustinecontaining regimen suggests the importance of testing the safety
and efﬁcacy of rituximab maintenance in a randomized clinical trial.35
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The MALT-IPI based on age $70 years, elevated LDH, and Ann
Arbor stage III/IV is a valuable stratiﬁcation tool to identify patients
at risk of shorter survival.27 Further, 3 independent cohorts demonstrated shorter survival in patients with EMZL experiencing POD24
from diagnosis.5,44,45 Prior studies established the failure to achieve
CR after frontline therapy as an important prognostic factor in
EMZL.5,46 In the cohort reported herein, we observed a high CR
rate; consequently, only a few events occurred in the ﬁrst 24
months after BR therapy, likely contributing to the ﬁndings that
MALT-IPI did not predict survival. The high efﬁcacy of BR might
overcome known poor prognosis features and will need to be
veriﬁed in future studies.
Inherent to all retrospective analyses, our study is limited by the lack
of data on indications for treatment selection, initiation, bendamustine dosage, and treatment length. Advanced stage disease and
good ECOG PS were frequently observed in our cohort, and these
features may have inﬂuenced BR selection over other regimens. We
did not have enough data to analyze the effect of t(11;18) in this
population, but it does not seem to affect response to BR based on
previously published reports.24
In summary, BR is a highly effective regimen in upfront treatment of
EMZL, capable of inducing durable remissions and possibly overcoming known adverse prognosis factors. We identiﬁed presence
of B symptoms as the only factor associated with worse outcome in
patients treated with BR. In contrast, rituximab maintenance was
associated with longer PFS but no impact on OS, underscoring the
need to conﬁrm these results in a randomized study before integrating this approach into clinical practice. Importantly, we observed
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The timing of treatment initiation for advanced-stage EMZL remains
controversial, with current guidelines recommending therapy initiation based on Groupe d’Etude des Lymphomes Folliculaire (GELF)
criteria.22 However, these criteria were designed for follicular lymphoma and extrapolated, without conﬁrmation, to patients with
EMZL. Whether GELF criteria are appropriate to determine therapy
initiation in EMZL remains unclear and unanswerable with this dataset. Single-agent rituximab demonstrated clinical activity in a study
including 34 patients with untreated and relapsed EMZL. In
chemotherapy-naïve patients (n 5 23), rituximab achieved an ORR
of 87% with CR rate of 48% and median time to treatment failure
of 22 months.14 Nevertheless, subsequent studies demonstrated
moderate activity of single-agent rituximab with lower rates of
responses and early relapses in patients not achieving CR.13,28,29
Our results support the selection of BR in patients with advancedstage EMZL requiring therapy initiation, leading to excellent results
with prolonged remissions.

Immunosuppression characterized by CD41 lymphopenia is common after bendamustine administration, usually lasting for 7 to 9
months upon completion of therapy.20,36 CD41 lymphopenia is
associated with cumulative bendamustine dose and is independent
of absolute lymphocyte recovery.37 A systematic review and metaanalysis of randomized controlled trials (n 5 2620 patients) demonstrated no effect of bendamustine on the rate of infections (relative
risk: 1.09) compared with alkylating agents or ﬂudarabine.38 Similarly, evaluating Medicare beneﬁciaries treated with BR for B-cell
lymphomas, Olszewski et al observed only a slight absolute increase
in infections and pneumonia risks (0.9 per 100 person-months and
0.6, respectively) during the second year after BR compared with
R-CHOP and R-CVP.39 A retrospective analysis in 82 patients with
chronic lymphocytic leukemia treated with frontline BR suggested
the need for herpes zoster prophylaxis beyond 8 months.40 We
observed infections associated with herpes zoster during therapy
with BR in 4% of patients, an observation previously not described
in clinical trials.18,23-25 Thus, our data suggest integrating herpes
zoster vaccination prior to starting therapy or prophylaxis during, and
probably beyond, BR treatment. Furthermore, because myelosuppression correlates with cumulative doses of bendamustine, a
response-adapted approach proposed by Salar et al25 may
decrease the incidence of infections warranting evaluation in randomized clinical studies. Similar to prior reports evaluating extended
adverse events in patients treated with bendamustine,41,42 we
observed no excess of secondary malignancies associated with
BR.31,43 However, higher incidence of nonmelanoma skin cancer
was reported in the BR arm in the 5-year follow-up of BRIGHT
study, highlighting the need for regular skin cancer screening upon
therapy completion.43

frequent infections attributed to herpes zoster, highlighting the need
to consider prophylaxis during BR treatment. Overall, BR is an excellent regimen for upfront treatment of patients with EMZL with
advanced-stage disease requiring treatment.
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